文献速递血脂与心血管预防

PCSK9抑制剂安全性:系统综述与荟萃分析

Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis.
PubMed 文献 · Heart · 2022-07-27

结果显示PCSK9抑制剂轻度增加严重注射部位反应风险,但不增加新发糖尿病、神经认知事件、白内障、胃肠道出血或严重肌痛风险。

要点

  • PCSK9抑制剂轻度增加严重注射部位反应导致停药风险,5年绝对发生率15例/1000人。
  • 高确定性证据表明PCSK9抑制剂不增加新发糖尿病、神经认知事件、白内障或胃肠道出血风险。
  • 中等确定性证据表明PCSK9抑制剂可能不增加肌痛或肌肉疼痛导致停药及任何不良事件导致停药风险。

核心结论

  • PCSK9抑制剂轻度增加严重注射部位反应风险,但不增加白内障、胃肠道出血、神经认知事件、新发糖尿病或严重肌痛风险。

主要发现

  • 注射部位反应导致停药的绝对发生率为5年每1000人15例事件(95%CI 11至20),高确定性证据。
  • 高确定性证据表明PCSK9抑制剂不增加新发糖尿病、神经认知事件、白内障或胃肠道出血风险。
  • 中等确定性证据表明PCSK9抑制剂可能不增加肌痛或肌肉疼痛导致停药或任何不良事件导致停药风险。
  • 极有限证据表明PCSK9抑制剂可能不增加流感样症状导致停药(RR 1.5;95%CI 0.06至36.58)。
  • 未发现可信的亚组分析结果,包括试验随访时间较短与较长的比较。

临床怎么用

  • 临床使用PCSK9抑制剂时应关注注射部位反应,严重者可能导致停药。
  • 基于高确定性证据,无需因担心新发糖尿病、神经认知事件、白内障或胃肠道出血而限制PCSK9抑制剂使用。

局限性

  • 未发现可信的亚组分析结果,包括随访时间长短的亚组比较。
  • 流感样症状导致停药的证据非常有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy. METHODS: This systematic review included randomised controlled trials that compared PCSK9 inhibitors with placebo, standard care or active lipid-lowering comparators in people who need lipid-lowering therapy with the follow-up duration of at least 24 weeks. We summarised the relative effects for potential harms from PCSK9 inhibitors using random-effect pairwise meta-analyses and assessed the certainty of evidence using GRADE (Grading of Recommendation Assessment, Development and Evaluation) for each outcome. RESULTS: We included 32 trials with 65 861 participants (with the median follow-up duration of 40 weeks, ranging from 24 to 146 weeks). The meta-analysis showed an incidence of injection-site reaction leading to discontinuation (absolute incidence of 15 events (95% CI 11 to 20) per 1000 persons in a 5-year time frame, high certainty evidence). PCSK9 inhibitors do not increase the risk of new-onset diabetes mellitus, neurocognitive events, cataracts or gastrointestinal haemorrhage with high certainty evidence. PCSK9 inhibitors probably do not increase the risks of myalgia or muscular pain leading to discontinuation or any adverse events leading to discontinuation with moderate evidence certainty. Given very limited evidence, PCSK9 inhibitors might not increase influenza-like symptoms leading to discontinuation (risk ratio 1.5; 95% CI 0.06 to 36.58). We did not identify credible subgroup analyses results, including shorter versus longer follow-up duration of trials. CONCLUSIONS: PCSK9 inhibitors slightly increase the risk of severe injection-site reaction but not cataracts, gastrointestinal haemorrhage, neurocognitive events, new-onset diabetes or severe myalgia or muscular pain.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Li J, Du H, Wang Y, et al. Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis. Heart. 2022. PMID: 35508401. doi:10.1136/heartjnl-2021-320556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。